Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study

Background Safinamide is a recent multimodal antiparkinsonian drug that inhibits monoamine oxidase B and modulates the glutamatergic system with positive effects on motor and nonmotor symptoms of Parkinson's disease (PD). This post-hoc analysis of the European SYNAPSES study provides first-time data on the use of safinamide in routine clinical practice in Belgium. Objective To describe the efficacy and safety of safinamide in Belgian PD patients in real-life conditions. Methods Post-hoc analysis of the Belgian cohort from the European SYNAPSES trial, which was an observational, multicenter, re... Mehr ...